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Oncogene-induced senescence (OIS) and therapy-induced senescence (TIS), while tumor-suppressive, also promote
procarcinogenic effects by activating the DNA damage response (DDR), which in turn induces inflammation. This
inflammatory response prominently includes an array of cytokines known as the senescence-associated secretory
phenotype (SASP). Previous observations link the transcription-associatedmethyltransferase and oncoproteinMLL1
to the DDR, leading us to investigate the role of MLL1 in SASP expression. Our findings reveal direct MLL1
epigenetic control over proproliferative cell cycle genes: MLL1 inhibition represses expression of proproliferative
cell cycle regulators required for DNA replication and DDR activation, thus disabling SASP expression. Strikingly,
however, these effects of MLL1 inhibition on SASP gene expression do not impair OIS and, furthermore, abolish the
ability of the SASP to enhance cancer cell proliferation. More broadly, MLL1 inhibition also reduces “SASP-like”
inflammatory gene expression from cancer cells in vitro and in vivo independently of senescence. Taken together,
these data demonstrate thatMLL1 inhibitionmay be a powerful and effective strategy for inducing cancerous growth
arrest through the direct epigenetic regulation of proliferation-promoting genes and the avoidance of deleterious
OIS- or TIS-related tumor secretomes, which can promote both drug resistance and tumor progression.
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senescence; inflammation]
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Numerous DNA-damaging cellular stresses, including
both oncogene activation and DNA-damaging chemo-
therapeutics, may lead to cellular senescence (van
Deursen 2014). Although senescent cells are tumor-sup-
pressive, they paradoxically possess deleterious effects
through the secretion of numerous inflammatory cyto-
kines and growth factors known as the senescence-associ-
ated secretory phenotype (SASP) (Coppe et al. 2010).
Indeed, the SASP is a driving force behind the low-level
chronic inflammation that causes or exacerbates many
age-related diseases, such as cancer (Rodier and Campisi
2011; Munoz-Espin and Serrano 2014). SASP secretion
leads to pleiotropic effects, including the pathological in-
creased proliferation of premalignant and malignant cells
(Coppe et al. 2006; Wang et al. 2006; Neves et al. 2015).
Hence, approaches to separate the beneficial tumor-sup-
pressive growth arrest of senescence from the deleterious
secretion of the SASP would be of significant clinical val-
ue (Coppe et al. 2010; Munoz-Espin and Serrano 2014; van
Deursen 2014). Indeed, recent studies have shown that the
mechanism of the anti-aging and anti-cancer effects of the
diabetes medication metformin may be through SASP in-
hibition (Algire et al. 2012; Moiseeva et al. 2013).
Given these important roles and consequences, the
SASP is regulated at multiple levels, involving various
transcription factors (NF-κB and C/EBPβ) (Kuilman et al.
2008; Chien et al. 2011) and kinases (p38MAPK and pro-
tein kinase D1) (Freund et al. 2011; Wang et al. 2014).
Importantly, however, activation of the DNA damage re-
sponse (DDR) is fundamentally required for SASP activa-
tion (Di Micco et al. 2006; Rodier et al. 2009; Coppe
et al. 2011). In contrast, mechanisms that underlie epige-
nomic regulation of the SASP are relatively unknown.
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Therefore, given the critical role of the transcriptional ac-
tivator and oncoprotein MLL1 in the mammalian DDR
(Liu et al. 2010; Rao and Dou 2015), we investigated the
role of MLL1 in SASP expression. We demonstrate that
MLL1 is required for the expression of proproliferative
cell cycle genes that are, in turn, necessary for triggering
the DDR and its resulting inflammatory signaling path-
ways, including the SASP. Our results provide evidence
that MLL1 inhibition may be an important therapeutic
strategy to inhibit the potentially deleterious aspects of
both the oncogene-induced senescence (OIS)-induced
and therapy-induced senescence (TIS)-induced SASP and
SASP-like inflammation while avoiding senescence es-
cape and cancer. Indeed, as increasing evidence suggests
that therapy-induced inflammation can lead to tumor pro-
gression, drug resistance, and metastasis (Obenauf et al.
2015; Shalapour and Karin 2015; Zelenay et al. 2015),
MLL1may prove an ideal primary or adjuvant target in or-
der to simultaneously inhibit cancerous proliferation and
the inflammatory side effects.
Results
MLL1 inhibition dramatically attenuates
SASP expression
We used a standard model of DNA damage-induced OIS
via 4-hydroxytamoxifen (4-OHT)-induced expression of
the H-Ras V12 (Serrano et al. 1997) oncogene in IMR90
fibroblasts. Senescence was confirmed by standard senes-
cence-associated β-galactosidase (SA-β-gal) staining (Sup-
plemental Fig. S1A,B) and other markers of senescence
using RNA sequencing (RNA-seq), such as up-regulation
of the tumor suppressor CDKN2A and down-regulation
of cyclin-dependent kinase genes such as CDK2 and the
nuclear lamina protein and senescence marker, LMNB1
(Supplemental Fig. S1C). We examined the effect of
MLL1 ablation on SASP expression in senescence using
shRNAs designed against MLL1 mRNA. As a control,
we treated both normal proliferating cells and OIS cells
with scrambled control (SC) shRNAs (referred to as
SC and SC OIS, respectively, hereafter). As expected, in
OIS, MLL1 shRNA-treated cells (MLL1 knockdown CTL
andMLL1 knockdownOIS, respectively) consistently dis-
played decreased levels of MLL1 in comparison with
SC OIS cells (Supplemental Fig. S1D,E).
Using RNA-seq, we identified the most up-regulated
genes (>1.5-fold increase in mRNA expression) from
scrambled control (SC) cells to SC OIS as well as the
most down-regulated genes (>1.5-fold decrease in mRNA
expression) from SC OIS to MLL1 knockdown OIS (Sup-
plemental Table 1). These criteria identified 224 genes,
which represented the most differentially expressed in
OIS with and without MLL1 ablation. Gene ontology
(GO) analysis of these genes identified numerous catego-
ries associated with the SASP (i.e., “cytokine activity”
contained the most genes, while others included “chemo-
kine activity,” “cytokine receptor binding,” “growth fac-
tor activity,” and “growth factor receptor binding”; fold
enrichment > 5, P < 0.05) (Supplemental Fig. S1F).
Direct examination of the top 20 most highly up-regu-
lated SASP genes identified in this analysis demonstrated
broad and dramatic reductions in expression of canonical
SASP genes (Freund et al. 2010) in MLL1 knockdown OIS
cells compared with SC OIS cells (P = 0.03 for SASP gene
reduction; P = 0.18 for all other genes) (Fig. 1A). For exam-
ple, IL1β, a key inflammasome mediator and the most
highly up-regulated of all genes in the RNA-seq data set,
was reduced almost fivefold (Fig. 1A, far left). Other genes
with profound reductions in expression included standard
SASP genes such as IL1A, IL8, IL6,MMP1, andMMP3 (Fig.
1A). We confirmed these results by RT-qPCR to examine
expression of three representative SASP genes, IL1A,
IL1B, and IL8 (Fig. 1B), given that they are themost highly
up-regulated SASP genes in IMR90 OIS (including in our
RNA-seq data) (Freund et al. 2010) and because IL1α has
a critical upstream role in inducing many downstream
SASP factors (Acosta et al. 2013). Furthermore, these spe-
cific genes are emerging as critical potential targets in nu-
merous human cancers (Crusz and Balkwill 2015). We
further verified these results using a second MLL1
shRNA, which recapitulated the reduction in SASP gene
expression via RT-qPCR (Supplemental Fig. S1G). As an
additional confirmation of SASP reduction in MLL1
knockdown OIS cells, we performed enzyme-linked im-
munosorbent assays (ELISAs). This assay assesses secret-
ed levels of canonical SASP factors within conditioned
medium derived from either SCOIS or MLL1 knockdown
OIS cells. The ELISAs showed a clear reduction of all test-
ed SASP factors from MLL1 knockdown OIS cells com-
pared with SC OIS (Fig. 1C) in multiple biological
replicates. For example, SASP factors such as IL6, which
has been implicated in cancer-associated inflammation
(Crusz and Balkwill 2015), displayed a striking reduction
of ∼13-fold in MLL1 knockdown OIS conditioned medi-
um (Fig. 1C). Similarly, we performed Western blotting
for IL1α, a key upstream regulator of the SASP (Orjalo
et al. 2009; Acosta et al. 2013), and observed substantially
reduced IL1α in MLL1 knockdownOIS compared with SC
OIS cells (Fig. 1D). Together, these results strongly sup-
port our RNA-seq observations that MLL1 reduction at-
tenuates SASP expression.
To confirm that these results were not unique to H-Ras
V12-induced fibroblasts, we tested a second model of
OIS using primary human melanocytes (in lieu of fibro-
blasts). The primary melanocytes were induced to enter
senescence via a doxycycline-inducible form of the
BRAFV600E oncogene (diBRAF). This system models
the formation of a melanocytic nevus, a well-established
example of in vivo OIS (Michaloglou et al. 2005). As
with our fibroblast analysis, we examined the top 20
most up-regulated SASP genes in BRAF-induced melano-
cyte OIS by RNA-seq and observed a similar profile of the
most highly up-regulated SASP genes as compared with
the senescent fibroblasts, including IL1B, again the most
up-regulated of all genes in the melanocytes (Sup-
plemental Fig. S1H,I). Similar to HRAS-induced OIS,
previous data suggest that BRAF-induced OIS leads to cel-
lular hyperproliferation in vitro and in vivo (Zhu et al.
1998; Dankort et al. 2007) and that in vivo human nevi
Capell et al.
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display features of an activated DDR (Gorgoulis et al.
2005; d’Adda di Fagagna 2008; Sheu et al. 2012). Thus,
we performedMLL1 knockdown in diBRAFmelanocytes,
and, similar to the fibroblast system, this led to a reduc-
tion of bothMLL1 and SASP gene expression (Supplemen-
tal Fig. S1J). As an additional measure of the effect of
MLL1 inhibition, we used the commercial pharmacologic
MI-2-2, which inhibits MLL1 activity via blocking the in-
teraction betweenMLL1 and its essential cofactor, Menin
(Huang et al. 2012), and such inhibitors display anti-can-
cer activity in several human tumor types (Borkin et al.
2015; Malik et al. 2015; Zhu et al. 2015). Importantly,
pharmacological inhibition of MLL1 activity by MI-2-2
in fibroblasts also abrogated the SASP to the same extent
as shRNA-mediated knockdown of MLL1 as measured by
RT-qPCR (Fig. 1E). Thus, we confirmed in twoOISmodels
that decreasing MLL1 using shRNA reduction results in
reduced SASP expression and that pharmacological inhi-
bition of MLL1 activity similarly abrogated SASP ex-
pression. These observations demonstrate that MLL1
inhibition potently reduces SASP expression and suggest
that MLL1 has an essential and specific role in the path-
way to activate SASP in OIS.
MLL1 inhibition does not alter OIS growth arrest
Given this extensive SASP reduction, we tested whether
MLL1 inhibition affects factors required for normal onset
or maintenance of OIS. We performedWestern blot analy-
sis for the critical OIS tumor suppressor and senescence
mediator CDKN2A (p16) in SC, SCOIS, andMLL1 knock-
down OIS cells. We did not detect any decrease in p16 or
Ras protein expression in MLL1 knockdown OIS cells as
compared with SC OIS cells (Fig. 2A). Thus, importantly,
in spite of the dramatic reduction in SASP expression by
lowering MLL1 levels, neither oncogene expression nor
senescence itself was decreased. These observations are
consistent with previous findings that expression of
CDKN2A is primarily controlled by H3K27me3 levels
(Bracken et al. 2007; Agger et al. 2009; Barradas et al.
2009). We further confirmed these results with RT-qPCR
and RNA-seq and found that CDKN2A mRNA levels
were consistently higher in MLL1 knockdown OIS cells
compared with SC and SCOIS (Fig. 2B,C). RNA-seq exam-
ination of other hallmark senescence genes showed that
MLL1 knockdownOIS cells displayed increases in a num-
ber of tumor suppressors (CDKN1A, CDKN2A, and
R
el
at
iv
e 
m
R
N
A 
le
ve
ls 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
IL1A 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
IL1B 
0 
1 
2 
3 
4 
5 
IL8 
OIS + DMSO 
OIS + MI-2-2 
(10uM) 
OIS + MI-2-2 
(20uM) 
FP
K
M
 fo
ld
 c
ha
ng
e 
R
el
at
iv
e 
m
R
N
A 
le
ve
ls 
 
  
 
 
 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
IL1A 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
IL1B 
NS 
 
 
  
NS 
SC
   
  
-Tubulin 
S
C
 O
IS
 
   
  
M
LL
1 
K
D
 O
IS
 
   
  
IL1
M
LL
1 
KD
 C
TL
 
   
  
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
IL8 
SC 
SC OIS 
MLL1 
KD OIS 
0 
2 
4 
6 
8 
10 
12 
SC OIS/SC 
MLL1 KD OIS/SC OIS 
0 
20 
40 
60 
80 
100 
120 
140 
160 
Top 20 Most Highly Expressed SASP Genes (RNA-seq) 
TIMP2 
GMCSF 
SC OIS 
MLL1 KD 
OIS 
Pos. Ctl. 
Neg. Ctl. 
IL1
IL1
IL6
IL8
-1.01 
-0.89 
-5.67 
-2.64 
-13.14 
-1.99 
-19.00 
-2.62 
 egnahc dloF
-(SC OIS/MLL1 KD OIS) 
B
D
E
A
C
Figure 1. MLL1 inhibition dramatically attenuates
SASP expression. (A) Genome-wide RNA-seq, displayed
here as fold change from control (SC) FPKM (fragments
per kilobase permillionmapped fragments) values, dem-
onstrates a broad and striking reduction in the top 20
most highly up-regulated SASP genes in MLL1 knock-
down (KD) OIS cells (green) as compared with the SC
OIS cells (blue). (B) RT-qPCR performed in three biolog-
ical replicates confirms RNA-seq results of some of the
most highly expressed SASP genes (comparing MLL1
knockdown OIS cells in green with SC OIS cells in
blue). Control “SC” cells are shown in orange. (C ) An
ELISA array for themost highly up-regulated SASP genes
displays decreased secretion of all SASP factors in condi-
tioned medium derived from MLL1 knockdown OIS
cells in comparison with SC OIS cell-derived condi-
tioned medium. Image density values were calculated
by Licor Image Studio Lite and used to calculate the neg-
ative fold change [−(SC OIS/MLL1 knockdown OIS)],
which is displayed in blue. (D) Western blotting demon-
strates a significant reduction in protein levels of the key
upstream SASPmediator IL1α in MLL1 knockdown OIS
cells in comparison with SC OIS cells. (E) Pharmacolog-
ical inhibition of the MLL/Menin interaction with 10
µM MI-2-2 dramatically reduces SASP expression by
RT-qPCR in comparison with OIS cells treated with ve-
hicle only (DMSO). Furthermore, treatment with both
10 and 20 µM doses of MI-2-2 demonstrates a dose re-
sponsiveness to SASP inhibition. Log values are reported
here so that they may be compared on a similar scale.
MLL1 inhibition prevents inflammation
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CDKN2B) and decreases in LMNB1 and cyclin genes
(CDK2 andCDK4) (Fig. 2C) to levels that are typical of sen-
escence in our assays. Importantly, OIS fibroblasts treated
with the MLL1/Menin inhibitor MI-2-2 also stained posi-
tively for SA-β-gal in percentages similar to those of
normal OIS cells (Fig. 2D,E), further arguing against im-
paired OIS induction or maintenance as an explanation
for our findings.We thenmeasured cell proliferationunder
MLL1 inhibition for both normal andOIS cells. Treatment
with 10 µMMI-2-2 repressed cellular proliferation in both
normal cells and cells harboring an activated oncogenic
HRasV12 (Fig. 2F).These results are consistentwith recent
evidence using a similarMLL1 inhibitor,MI-503, inMLL1
leukemia cells (Borkin et al. 2015). Intriguingly, while nor-
mal OIS cells underwent an initial period of hyperprolifer-
ation in the first 48 h upon Ras induction, this effect was
not observed in cells treated with MI-2-2 (Fig. 2F). Thus,
MLL1 inhibition strikingly attenuates the SASP while
having no effect on the tumor-suppressive growth arrest.
MLL1 inhibition blocks DDR-induced inflammation
independently of senescence
We next determined whether MLL1 inhibition might
function more broadly to regulate inflammatory gene ex-
pression in the contexts of both DNA damage and cancer.
Thus, we tested whether MLL1 inhibition would simi-
larly block cytokine and “SASP-like” gene expression
following DNA damage, specifically independently of
senescence. To do this, we treated normal proliferating fi-
broblasts with the DNA-damaging chemotherapeutic
agent etoposide. Cells exposed to etoposide and harvested
after 48 h, prior to the onset of senescence, displayed sig-
nificant up-regulation of SASP genes such as IL1A, IL1B,
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Figure 2. MLL1 inhibition has no effect on
OIS growth arrest and blocks DDR-induced
inflammation independently of senes-
cence. (A) Western blotting shows that
both Ras and CDKN2A/P16 levels are un-
changed in MLL1 knockdown (KD) OIS
cells in comparison with SC OIS cells. (B)
RT-qPCR confirms that CDKN2A mRNA
levels increase in MLL1 knockdown OIS
cells (green) and are higher than those in
SC OIS cells (blue). (C ) RNA-seq demon-
strates thatMLL1 knockdownOIS cells fol-
low transcriptional patterns typically seen
in OIS, including increased levels of tumor
suppressors CDKN1A, CDKN2A, and
CDKN2B as well as decreases in nuclear
lamina component LMNB1 and cyclin-de-
pendent kinases CDK2 and CDK4. (D,E)
SA-β-gal staining (D) and its quantification
(E) show that MI-2-2-treated cells express
SA-β-gal in percentages similar to those of
normalOIS cells treatedwithDMSO,while
control cells do not. (F ) A growth curve
analysis demonstrates that MLL1 inhibi-
tion by MI-2-2 slows proliferation in both
control and OIS cells and prevents the
hyperproliferative period typically seen fol-
lowing oncogene induction during the first
48 h of OIS onset. (G) Normal proliferating
IMR90 fibroblasts exposed to the DNA-
damaging agent etoposide for 48 h are un-
able to express SASP genes in the setting
of a single dose of 10 µM MI-2-2 given at
the same time as the etopside, in contrast
to DMSO-treated cells. (H) MCF7 human
breast cancer cells were likewise treated
in the same manner with etoposide and
similarly were unable to up-regulate in-
flammatory cytokines.
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and IL8 (Fig. 2G). Importantly, the addition of the MLL1
inhibitor MI-2-2 abrogated this up-regulation of SASP
genes (Fig. 2G). Similar results were obtained by repeating
this experiment in MCF7 breast cancer cells (which up-
regulated SASP genes IL6 and IL8 but not IL1A or IL1B
significantly) (Fig. 2H), mimicking the clinical scenario
of TIS or DNA damage-induced tumor secretomes (Obe-
nauf et al. 2015). Together, these data indicate that
MLL1 inhibition may prevent DNA damage-induced cy-
tokine secretion and inflammation from both normal
and cancerous cells independently of senescence.
MLL1 inhibition prevents the procarcinogenic effects of
the SASP and represses inflammation in cancer in vivo
We next assessed the functional consequences of MLL1
inhibition on DDR-induced cytokine/SASP expression
using a cellularmigration assaywith conditionedmedium
from senescent cells. This assay has been used as a stan-
dard measure to assess the functional effects of secreted
factors in numerous contexts, including in senescence
and cancer, to show the functional effects of secreted fac-
tors on premalignant and malignant cells (Jenei et al.
2009; Walter et al. 2010; Yew et al. 2011; Canino et al.
2012; Sun et al. 2012; Justus et al. 2014). Conditioned me-
dium derived from normal SC OIS cells substantially en-
hanced cellular migration of human MCF7 breast cancer
cells after 3 d (Fig. 3A, cf. day 1 and day 4, middle panels).
In contrast, conditioned medium derived from MLL1
knockdownOIS cells did not stimulate or differentially af-
fect cellular migration, similar to medium derived from
control SC cells (Fig. 3A, cf. top and bottom panels). Image
analysis software quantified these results and confirmed
the inability of the MLL1 knockdown OIS medium to
enhance cancer cell migration (Supplemental Fig. S2A,
B). This observation further supports a model in which
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Figure 3. MLL1 inhibition prevents the
procarcinogenic effects of the SASP and in-
hibits inflammation in cancer in vivo. (A)
Cellular proliferation assay of MCF7 breast
cancer cells exposed to conditioned medi-
um from either SC cells (top panels), SC
OIS cells (middle panels), or MLL1 knock-
down (KD) OIS cells (bottom panels) dem-
onstrates that while SC OIS cell medium
containing a normal amount of the secreted
SASP leads to enhanced cellular growth and
migration of this cancer, the medium de-
rived from the MLL1 knockdown OIS cells
does not and is more comparable with the
SC cells that have no SASP. (B) RT-qPCR
of xenograft tumors demonstrates that tu-
mors derived fromMLL1 shRNA-treated tu-
mors display significantly less expression of
MLL1, IL1A, IL1B, and IL6 as compared
with those tumors derived from SC shRNA
treatment. (C ) Immunofluorescence (IF)
(20×) of tumor sections also demonstrates
reduced expression of IL1α (green) and IL6
(red) in tumors derived from the MLL1
shRNA-treated tumors as compared with
tumors derived from SC shRNA treatment.
(D) The average of the quantification of
three representative 20× IF fields from tu-
mor sections shows thatMLL1-inhibited tu-
mors express significantly fewer foci of IL1α
and IL6 than SC shRNA-treated tumors. (E)
An examination of 1215 human breast can-
cer patient samples from The Cancer Ge-
nome Atlas (TCGA) demonstrates that the
highest one-third of MLL1-expressing tu-
mors have significantly higher SASP expres-
sion (IL1B and IL6 shown here) than tumors
in the lowest one-third ofMLL1 expression.
MLL1 inhibition prevents inflammation
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MLL1 inhibition can reduce SASP expression and thus
prevent the previously described procarcinogenic, propro-
liferative functions.
MLL1 inhibitors have recently been shown to have anti-
proliferative and anti-cancer effects in successfully treat-
ing mouse models of cancer in vivo (Borkin et al. 2015;
Malik et al. 2015; Zhu et al. 2015). However, the effects
ofMLL1 inhibition on proinflammatory cytokine gene ex-
pression in cancer in vivo is unknown. AsMI-2-2 does not
have in vivo biological activity, in order to answer this
question, we performed tumor xenografts. Human breast
cancer cells were stably infected with lentivirus encoding
either SC or MLL1 shRNAs and injected into mice sub-
cutaneously to allow for tumor formation. The tumors
were harvested and subjected to cytokine gene expression
analyses. Decreased expression of both MLL1 and SASP-
like cytokine genes, including IL1A, IL1B, IL6, and
MMP1, were detected by RT-qPCR (Fig. 3B). Protein levels
were also reduced, as immunofluorescence (IF) assays
demonstrated repressed levels of IL1α and IL6 (Fig. 3C;
Supplemental Fig. S2D). IL1α and IL6 colocalized, and
quantification of IL1α/IL6 foci in multiple 20× fields con-
firmed decreased levels of SASP expression (Fig. 3D). To-
gether, these results suggest that inhibiting MLL1 in
vivo can decrease SASP-like inflammatory gene expres-
sion and suggest a possible additional novel mechanism
by which MLL1 inhibition is effective for cancers in
vivo (Borkin et al. 2015; Malik et al. 2015).
Next, we analyzed clinical tumor samples from human
breast cancers using The Cancer Genome Atlas (TCGA).
Examining all samples (1215) and extracting those with
both the highest and lowest one-third ofMLL1 expression,
we observed a significant positive correlation between
highMLL1 expression and high SASP gene expression, in-
cluding IL1A, IL1B, IL6, and IL8 (Fig. 3E; Supplemental
Fig. S3A, with corresponding P-values), which was not ev-
ident for control housekeeping genes such as GAPDH,
ACTB, and LMNA (Supplemental Fig. S3A). We then ex-
amined another common human cancer, prostate cancer
(551 total samples), and found similar positive correla-
tions, as patient tumor samples with the highest expres-
sion of MLL1 also had significantly higher levels of
SASP gene expression, including IL1A, IL1B, and IL8 (Sup-
plemental Fig. S3B, with P-values included). These trends
were also not present for control housekeeping genes, in-
cluding ACTB, GAPDH, and LMNA (Supplemental Fig.
S3B). Together, these results demonstrate thatMLL1 inhi-
bition prevents the expression of these SASP-like inflam-
matory genes in vivo in human cancer xenografts and are
further supported by our discovery of a novel in vivo cor-
relation between MLL1 and SASP gene expression in hu-
man patient cancer samples.
MLL1 inhibition leads to greater losses of γH2A.X
than H3K4me3 enrichment over SASP genes
To further assess the epigenomic effect of MLL1 on the
SASP, we performed ChIP-seq (chromatin immunoprecip-
itation [ChIP] combined with deep sequencing) for
H3K4me3 and γH2A.X. MLL1 deposits H3K4me3 at tran-
scriptional start sites (TSSs) (Rao and Dou 2015), and an
activatedDDR leads to the phosphorylation of the histone
variant H2A.X (called γH2A.X) that occurs surrounding
sites of DNA breaks (Rogakou et al. 1999). We performed
ChIP-seq for H3K4me3 and γH2A.X in control (both CTL
and SC cells), normal OIS (as well as SC OIS), and MLL1
knockdown OIS cells using either Hi-Seq or NextSeq
platforms using total histone and input as controls. We
found that the most highly up-regulated SASP genes by
RNA-seq, such asMMP1 and IL1B, displayed extensive in-
creases in both H3K4me3 and γH2A.X binding during OIS
(Fig. 4A; Supplemental Fig. S4A). Indeed, when the top 1%
most highly expressed genes in OIS were plotted by levels
of expression (as measured by RNA-seq) and γH2A.X (as
measured by ChIP-seq) and colored by levels of
H3K4me3 (Supplemental Fig. S4B, in red), SASP genes dis-
played some of the largest increases in these measures in
OIS (Supplemental Fig. S4B, SASP genes highlightedwith-
in the red box). Intriguingly, rather than broad megabase
domains of γH2A.X, as typically observed adjacent to
DNA double-strand breaks (Rogakou et al. 1999), the in-
creases over the SASP genes were extensive yet restricted
to gene bodies (Fig. 4A; Supplemental Fig. S4A). We note
that this novel observation of dramatic gene body enrich-
ment in γH2A.X was similarly observed recently in asso-
ciation with neuronal response genes undergoing rapid
activation (Madabhushi et al. 2015). Future investigations
will likely determine the function of γH2A.X in this
setting.
We next determined the effect of MLL1 depletion on
these chromatin changes. H3K4me3 ChIP-seq in MLL1
knockdownOIS cells demonstrated that some SASP genes
have reduced H3K4me3, including MMP1, MMP10,
SERPINB2, CXCL3, and CCL3 (Fig. 4B). However, the
overall loss of H3K4me3 enrichment was modest and
did not correspond well to the dramatic decreases in tran-
scription of the SASP (P = 0.42), as some prominently re-
pressed genes did not lose any H3K4me3, such as IL1A
and IL1B (Fig. 4B,C). In contrast, decreases in gene body
γH2A.X in MLL1 knockdown OIS were more extensive
and were detected for almost all down-regulated SASP
genes (P = 0.02; Fig. 4B), includingMMP1 as a clear exam-
ple (Fig. 4D). Together, these ChIP-seq data suggest that
the most up-regulated SASP genes possess a consistent
epigenetic signature marked by large enrichment of both
H3K4me3 and γH2A.X in OIS. Importantly, though, the
effects of MLL1 inhibition did not correlate strongly to re-
ductions inH3K4me3 enrichment at SASP genes but rath-
er, apparently, through an independent effect on DDR
signaling to the SASP genes, as reflected in a consistent
decrease in γH2A.X enrichment.
MLL1 inhibition in OIS prevents activation
of the ATM–NF-κB signaling axis
We reasoned that MLL1 might have a direct effect on the
DDR, which then potentially manifests in the changes
that we observed in SASP gene expression. To test this,
we first examined whether MLL1 inhibition altered acti-
vation of the DDR. We performed RT-qPCR for ATM,
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which is essential for SASP activation (Rodier et al. 2009)
and phosphorylates the key SASP transcription factor NF-
κB p65 (phospho-S536) (Piret et al. 1999; Huang et al. 2003;
Wu et al. 2006). We observed significant reduction of
ATM mRNA levels in MLL1 knockdown OIS cells com-
pared with SC OIS cells (Fig. 5A). Western blotting like-
wise demonstrated decreased levels of total ATM
protein, including its activated form, ATM phospho-
S1981 (Fig. 5B). To visualize this loss of ATM in cells,
we performed IF for ATMphospho-S1981 inMLL1 knock-
down OIS cells as compared with normal SC and SC OIS
cells and quantified positively staining nuclear puncta.
MLL1 knockdown OIS cells consistently displayed signif-
icantly reduced numbers of ATM phospho-S1981 nuclear
puncta in comparison with SC OIS cells (Fig. 5C,D; Sup-
plemental Fig. S4C). We also performed Western blotting
for ATM phospho-S1981 using control or OIS cells treated
with MI-2-2. Similar to MLL1 shRNA treatment, we ob-
served reduced ATM phospho-S1981 in OIS cells treated
with MI-2-2 to levels seen in control proliferating cells
(Fig. 5E). As a control, this reduction was similar to the ef-
fect of a specific inhibitor of phospho-ATM (KU55933) on
OIS cells (Fig. 5E), which also effectively inhibited the
SASP genes IL1A, IL1B, and IL8 (Supplemental Fig. S4D;
Rodier et al. 2009).
We examined this relationship between ATM expres-
sion and MLL1 further by looking at clinical tumor sam-
ples from TCGA (Cerami et al. 2012; Gao et al. 2013).
Similar to SASP genes as described above (Fig. 3E; Supple-
mental Fig. S3A,B), tumors with the highest levels of
MLL1, also displayed significantly higher levels of ATM
(Supplemental Fig. S3A,B). Remarkably, upon closer ex-
amination, we observed that MLL1 was among the most
highly coexpressed geneswithATM in each type of human
Figure 4. MLL1 inhibition leads to greater
losses of γH2A.X than H3K4me3 enrich-
ment over SASP genes. (A) ChIP-seq tracks
display dramatic increases in H3K4me3
(blue) over SASP gene promoters and
γH2A.X (green) over SASP gene bodies in
OIS as compared with control proliferating
cells (CTL), as seen here over the SASP
gene MMP1. (B) Heat map based on ChIP-
seq (first through fourth columns) and
RNA-seq (fifth column) of SC, SC OIS, and
MLL1 knockdown (KD) OIS cells of all
SASP genes demonstrates that many, but
not all, SASP genes gain H3K4me3 (as mea-
sured over the promoter and TSS) in the
transition from proliferating SC cells to
OIS (SC OIS) (first column). When compar-
ing H3K4me3 levels by ChIP-seq between
SC OIS cells and MLL1 knockdown OIS
cells (second column), some SASP genes
lose H3K4me3 enrichment inMLL1 knock-
down OIS cells, although the changes are
not uniform and do not correlate well with
expression changes. In contrast, almost all
SASP genes demonstrate both increases in
γH2A.X enrichment (as measured over the
gene body) going from the control (SC) to
the OIS (SC OIS) state (third column) as
well as decreases in γH2A.X enrichment
with MLL1 knockdown in OIS (MLL1
knockdownOIS) (fourth column). (C ) Delta
track of H3K4me3 ChIP-seq data (MLL1
knockdown OIS/SCOIS) demonstrates rep-
resentative SASP genes (IL1A and IL1B)
that, despite decreasing extensively in ex-
pression with MLL1 knockdown, do not
lose, but rather actually gain, H3K4me3
enrichment with MLL1 knockdown. (D)
ChIP-seq track views over a representative
SASP gene (MMP1) display modest decreas-
es in promoter H3K4me3 levels but more
extensive losses in gene body γH2A.X levels
inMLL1 knockdownOIS cells as compared
with SC OIS cells. SC proliferating cell
tracks are labeled as SC here.
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cancer examined for which RNA-seq expression datawere
available (Supplemental Fig. S5A). For example, compar-
ing 20,444 genes ranked from 1098 invasive breast cancer
samples, MLL1 was the second most highly coexpressed
gene with ATM (Pearson’s correlation, 0.77) (Supplemen-
tal Fig. S5B; Cerami et al. 2012; Gao et al. 2013). This
strong positive correlation held for each of the 24 cancer
types analyzed. Global analysis combining data from all
24 TCGA cancer types showed that MLL1 is the second
most highly coexpressed gene with ATM across all cancer
types (Fig. 5F; Supplemental Fig. S5C).MLL1 coexpression
with ATM was higher than several genes with known
functional relationships with ATM in theDDR, including
MRE11A and SMG1 (Fig. 5F). Notably, the only gene that
was more highly coexpressed with ATM than MLL1 was
NPAT, which shares a bidirectional promoter with ATM
(Fig. 5F; Imai et al. 1996). The robustness of the observed
correlation between MLL1 and ATM mRNA abundance
in such a large and diverse set of human cancers in vivo
is supportive of this potential functional relationship
that we observed here with MLL1 in vitro.
Consistent with the decreased levels of chromatin-
bound γH2A.X observed in the ChIP-seq data as well as
with the failure of ATM activation, MI-2-2 also displayed
Figure 5. MLL1 inhibition in OIS prevents
activation of the ATM–NF-κB signaling
axis. (A) ATMmRNA expression is reduced
in OIS cells treated with MLL1 shRNA
(MLL1 knockdown [KD] OIS; green) as com-
pared with SC OIS cells (blue) as measured
by RT-qPCR. SC proliferating cells are in or-
ange. (B) Western blotting shows thatMLL1
knockdownOIS cells have reduced levels of
both total ATM and activated ATM (phos-
pho-S1981) in comparison with SC OIS
cells. (C ) IF of MLL1 knockdown OIS cells
displays decreased activated ATM (phos-
pho-S1981) nuclear puncta (red) in MLL1
knockdown OIS cells as compared with
SC OIS cells. Blue staining indicates DAPI-
stained DNA, while pink staining repre-
sents the merged image. (D) Quantification
of the percentage of cells in SC, SCOIS, and
MLL1 knockdown OIS cells with at least
five positively staining red nuclear puncta
by IF demonstrates a significant reduction
in MLL1 knockdown OIS cells. SC OIS
compared with SC, P-value = 0.0015;
MLL1 knockdown OIS compared with SC
OIS, P = 0.0068. (E) ATM (phospho-S1981)
protein levels are also reduced by pharma-
cological treatment with aMLL1/Menin in-
teraction inhibitor, MI-2-2 (10 µM), which
prevents its H3K4me3 activity and is simi-
lar in efficacy to a targeted inhibitor of phos-
pho-ATM, KU55933 (10 µM). (F ) Ranking of
the top 20 genes that correlate with ATM
expression across all human cancers in
TCGA demonstrates that MLL1 is the sec-
ond most highly correlated gene from the
entire genome across all tested cancers, sec-
ond only to NPAT, which shares a bidirec-
tional promoter with ATM, and ahead of
genes with known functional relationships
with ATM (SMG1 and MRE11A). (G) IF of
OIS cells treated with MI-2-2 displays re-
duced foci of the DNA damage marker
γH2A.X as compared with DMSO-treated
OIS cells. (H) NF-κB p65 (phospho-S536),
which is downstream from activation of ATM and is a critical SASP transcription factor, was decreased in MLL1 knockdown OIS cells
in comparison with SC OIS cells. (I ) MLL1 knockdown OIS cells display no differences in total ATR or P53 levels from normal SC OIS
cells, suggesting that the effects of MLL1 inhibition are more specific for the ATM-mediated arm of the DDR and not just a global inhi-
bition of the DDR. (J) Consistent with repressed activation of ATM, which phosphorylates P53, P53 (phospho-S15) is decreased in MLL1
knockdown OIS cells as compared with normal SC OIS cells.
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reduced levels of nuclear γH2A.X foci by IF, a standard
measure of DNA damage (Fig. 5G). Furthermore, the
SASP transcription factor NF-κB p65 (phospho-S536) was
also decreased to levels seen in SC cells (Fig. 5H). To assess
the specificity of this effect on ATM, we assayed total lev-
els of otherDDReffectors, ATR and p53. Total ATR levels
were decreased in both SC OIS and MLL1 knockdown
OIS, consistent with cells that are no longer replicating
(Fig. 5I). Total p53 was likewise unchanged between SC
OIS and MLL1 knockdown OIS cells (Fig. 5I). In contrast
to total p53 levels and consistent with decreased levels
of ATM phospho-S1981, p53 phospho-S15, known to be
phosphorylated by activated ATM, was decreased in
MLL1 knockdown OIS cells as compared with SC OIS
cells (Fig. 5J). Taken together with our other observations,
our results demonstrate that both genetic inhibition and
pharmacologic inhibition of MLL1 level and activity sig-
nificantly reduce ATM-mediated DDR signaling, a re-
quired upstream regulator of SASP expression.
MLL1 directly regulates the expression of numerous
critical proproliferative cell cycle regulators
and cancer target genes
Since the dramatic attenuation of SASP expression with
MLL1 inhibition did not correspond to statistically signif-
icantly reduced levels of H3K4me3 at SASP gene promot-
ers, we looked more closely at the genes that were
significantly losing H3K4me3 with MLL1 reduction. We
performed GO analysis of the top 500 genes exhibiting
the greatest loss of H3K4me3 enrichment by ChIP-seq
in MLL1 knockdown OIS cells as compared with SC OIS
cells. This revealed gene categories enriched for critical
kinases and transcription factors required for both cell
cycle progression and checkpoint cascades, including acti-
vation of the DDR (fold enrichment > 5, P < 0.05) (Supple-
mental Fig. S6A; Di Micco et al. 2006; Cerqueira et al.
2009; Tian et al. 2009; Johnson and Shapiro 2010; Liu
et al. 2010; Shintomi et al. 2015; Sivakumar and Gorbsky
2015). These genes, including AURKA, AURKB, BIRC5,
CCNA2, CCNB2, CCNB1, CDC20, CDK1, CDK2,
CHEK1, FOXM1, KIF20A, MAD2L1, NCAPG, Polo-like
kinase 1 (PLK1), TOP2A, andUBE2C (examples displayed
in Fig. 6A; Supplemental Fig. S6B–G), exhibited more ex-
tensive losses of H3K4me3 (average loss of −0.657) than
even the Hox genes (average loss of −0.077), which
MLL1 is well known to regulate (Milne et al. 2002). Nota-
bly, many of these proproliferative genes, including Survi-
vin (BIRC5), Aurora kinases (AURKA and AURKB),
PLK1, FOXM1, and CDC20, are currently being targeted
for pharmacological reduction in a diverse array of can-
cers, as their high expression in patient tumor samples
correlates with worse survival (Gentles et al. 2015).
When all genes in the genome were plotted according to
levels of expression and H3K4me3, these proproliferative
cell cycle genes had clear reductions in expression (P =
0.02) that corresponded with their losses of H3K4me3 en-
richment with MLL1 knockdown in OIS (P = 7.0 × 10−8),
in striking contrast to SASP genes, which did not uniform-
ly lose H3K4me3 (Fig. 6B).
These observations suggest that MLL1 may be critical
for direct normal regulation of an array of proproliferative
cell cycle genes that have been implicated in cancer. We
examinedwhetherMLL1 knockdown also reduced the ex-
pression of these genes independently of senescence using
RNA-seq on normal proliferating fibroblasts treated with
MLL1 shRNA (MLL1 knockdown CTL). GO analysis of
the top 500 down-regulated genes in MLL1 knockdown
CTL cells compared with SC cells again demonstrated a
strong enrichment of the same proproliferative cell cycle
regulators (fold enrichment > 5, P < 0.05) (representative
genes displayed in Fig. 6C; Supplemental Fig. S6H). In-
deed, the intersection of all genes that were in the top
500 genes with maximum H3K4me3 reduction by ChIP-
seq with MLL1 knockdown in OIS and the top 500 genes
with the maximum reduced expression by RNA-seq with
MLL1 knockdown in normal proliferating cells (MLL1
knockdown CTL) identified 57 genes (P = 3.4 × 10−53) for
whichMLL1 likely has a direct role in regulating their ex-
pression through H3K4me3 (Fig. 6D).
To directly test the role of MLL1 in the regulation of
these proproliferative cell cycle genes, we overexpressed
MLL1 in cells that were simultaneously treated with
MI-2-2, hypothesizing that strongly increasing MLL1 lev-
els could potentially rescue the loss of expression of these
proproliferative cell cycle genes caused byMI-2-2.Normal
fibroblasts were treated with a single dose of 10 µM
MI-2-2, simultaneously transfected with either empty or
MLL1 overexpression plasmids, and harvested 48 h later
for mRNA analysis. As a control for transfection efficien-
cy, transfecting GFP into the same IMR90 fibroblasts
demonstrates that >80% of cells show GFP positivity
(Supplemental Fig. S6I,J). RT-qPCR results demonstrated
that transfection by the MLL1 overexpression plasmid
did result in a striking up-regulation of MLL1 mRNA by
>10,000-fold (Fig. 7A). Subsequent RT-qPCR of key pro-
proliferative cell cycle genes showed partial to complete
rescue of mRNA expression levels (Fig. 7B), suggesting
that the dramatic up-regulation of MLL1 simply over-
whelmed the capacity of the singleMI-2-2 dose to fully in-
hibit MLL1 activity and allowed for the continued
expression of these proproliferative cell cycle genes. Com-
bined with the above RNA-seq and ChIP-seq results as
well as previous data demonstrating a direct role for
MLL1 in controlling the expression of a subset of cyclin
genes (Takeda et al. 2006), this observation is highly sup-
portive of MLL1 having a direct role in the expression of
these proproliferative cell cycle genes.
Next, we examined the expression of these proprolifer-
ative cell cycle genes 48 h after oncogene activation dur-
ing the period of hyperreplication and prior to the onset
of OIS.MLL1 has been shown to be critical for progression
of S phase, and inhibition of normal S-phase replication
and checkpoint function impairs activation of the DDR,
including in OIS, where cells must first undergo a period
of hyperreplication to trigger the DDR (Di Micco et al.
2006; Cerqueira et al. 2009; Tian et al. 2009; Johnson
and Shapiro 2010; Liu et al. 2010)—hence our reasoning
for performing this analysis at 48 h after oncogene induc-
tion. Strikingly, the RT-qPCR results showed that MLL1
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knockdownOIS cells significantly down-regulated the ex-
pression of all tested proproliferative cell cycle genes be-
low the levels seen in SC OIS (Fig. 7C). In fact, while
CDK2 levelswere higher in SCOIS cells than proliferating
SC cells 48 h after oncogene activation, levels in MLL1
knockdown OIS cells were significantly reduced below
both SC and SC OIS cells (Fig. 7C). Taken with our other
results, this up-regulation likely occurs through the mod-
ification of H3K4me3. Finally, we arrested cells in G1
phase through serum starvation and then treated them
with the DNA-damaging agent etoposide. Strikingly,
and consistent with previous results (Di Micco et al.
2006), cells arrested in G1 were unable to activate the
DDR and induce inflammatory cytokines, including
IL1A, IL1B, IL6, and MMP1 (Fig. 7D). Thus, reduction of
MLL1 expression or activity prevents DDR activation
and SASP expression through its direct inhibition of the
expression of key genes necessary for proliferation, orderly
cell cycle progression, and triggering of the DDR (Fig. 7E).
Specifically, in contrast to normal OIS cells, MLL1-inhib-
ited cells are unable to have a normal progression through
the S-phase checkpoint due to the reduced expression of
proproliferative cell cycle genes and MLL1’s known re-
quired role for normal S-phase progression (Liu et al.
2010). In turn, these cells are unable to trigger the activa-
tion of the DDR and its key mediator for expression of the
SASP, ATM phospho-S1981. In contrast, tumor-sup-
pressive cell cycle genes that promote growth arrest,
such as CDKN1A and CDKN2A, remain elevated. To-
gether, this demonstrates how MLL1 inhibition enables
direct senescence growth arrest without induction of the
SASP gene network.
Discussion
In this study, we identified a novel functional relationship
between the chromatin regulator MLL1 and an array of
proproliferative cell cycle and cancer target genes that
control both proliferation and normal DDR engagement.
In our key observation, inhibition of MLL1 expression or
activity abrogates DDR-induced inflammatory cytokine
gene expression in senescence (the SASP) and in
Figure 6. MLL1 directly regulates the expression
of numerous critical proproliferative cell cycle and
cancer target genes. (A) ChIP-seq delta track
(MLL1 knockdown [KD] OIS/SC OIS) of
H3K4me3 enrichment at the genes CDK2,
AURKB, BIRC5, and CCNA2 demonstrates ex-
tensive losses of H3K4me3 at the promoter of
both genes in MLL1 knockdown OIS cells. (B)
Scatter plot of the log ratio of H3K4me3 enrich-
ment (ChIP-seq) and gene expression (RNA-seq)
of MLL1 knockdown OIS/SC OIS demonstrates
that proproliferative cell cycle and cancer target
genes (blue dots) lose both expression and
H3K4me3 enrichment in comparison with SASP
genes (red Xs) and all other genes (gray dots). (C )
RNA-seq of MLL1 knockdown in normal control
proliferating IMR90s (MLL1 knockdown CTL) in
comparison with SC cells demonstrates extensive
loss of expression of key proproliferative cell cycle
and cancer target genes (genes derived from the
top 500 genes that lost expression genome-wide,
displayed as the percentage of expression lost
with MLL1 knockdown). (D) The relative levels
of change for the 57 genes that were identified
from the intersection of the top 500 genes with
the most decreased H3K4me3 enrichment (ChIP-
seq) in MLL1 knockdown in OIS cells (MLL1
knockdown OIS) as well as the top 500 genes
with the most reduced expression (RNA-seq)
with MLL1 knockdown in control cells (MLL1
knockdown CTL) are displayed in heat map
form. The first column displays the fold change
of loss of expression in control cells with MLL1
knockdown by RNA-seq. The second column dis-
plays the loss of expression inOIS cellswithMLL1
knockdown by RNA-seq. The third column dis-
plays the loss of H3K4me3 in OIS cells with
MLL1 knockdown by ChIP-seq. Relative change
of H3K4me3 over ±1 kb of the TSS is shown. Eu-
clidean distance with ward metric hierarchical
clustering was used.
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chemotherapy-induced DNA damage independently of
senescence. Blockade of MLL1 also prevents the ability
of the SASP to promote the protumorigenic potential of
surrounding cancer cells and, importantly, similarly re-
presses inflammatory gene expression in cancer in vivo.
Remarkably, despite the strong attenuation of activated
ATM-mediated and NF-κB-mediated SASP expression,
the elevation of tumor suppressors such as p16 and p21
and the senescence growth arrest itself are unaffected.
This mechanistic uncoupling suggests a possible thera-
peutic role for MLL inhibition in inducing cancerous
growth arrest without the deleterious effects of drug resis-
tance and tumor progression caused by the SASP or che-
motherapy-related tumor inflammation.
AlthoughMLL1 has previously been shown to associate
with mitotic chromatin (Blobel et al. 2009) and regulate
A- and B-type cyclins (Takeda et al. 2006), our data demon-
strate that the crucial epigenetic regulatory role of MLL1
may bemuch broader andmay extend to the expression of
numerous cancer-promoting kinases and transcription
factors such as Aurora kinases (AURKA and AURKB),
Survivin (BIRC5), PLK1, and FOXM1. MLL1 inhibition
strongly lowers the expression of these genes, which is
likely the direct effect of the inhibitors on the cessation
of cell growth, and prevents the critical hyperreplica-
tive S-phase-dependent activation of the DDR. Beyond
MLL1’s direct chromatin effects on these proliferation-
promoting genes, inflammation has been shown to be a
“hallmark of cancer” (Hanahan and Weinberg 2011), and
the SASP has been shown to enable aspects of tumor pro-
gression through the induction of angiogenesis (Coppe
et al. 2006), epithelial–mesenchymal transition (EMT)
(Laberge et al. 2012), and the promotion of cancer stem-
like cells (Cahu et al. 2012). Thus, our findings provide fur-
ther rationale for testing MLL1 inhibitors as either mono-
therapy or adjuvant therapy in other cancers beyond those
recently shown to be responsive to MLL1 inhibition
(Borkin et al. 2015; Malik et al. 2015; Zhu et al. 2015).
Figure 7. (A) MLL1 overexpression by transient
transfection over 48 h demonstrates significant
up-regulation by >10,000-fold of MLL1 by RT-
qPCR as compared with vector control transfec-
tion. Notably, 10 µM MI-2-2 treatment has no ef-
fect on levels ofMLL1. (B) Normal control IMR90
cells were transfected with either a vector control
or MLL1 overexpression plasmid in the setting of
either a single dose of DMSO or 10 µMMI-2-2. Af-
ter 48 h, RT-qPCRwas performed and demonstrat-
ed that MLL1 overexpression either partially or
fully rescued the expression of proproliferative
cell cycle genes AURKA, AURKB, BIRC5,
CCNA2, andCDK2, suggesting thatMLL1hasadi-
rect role in regulating their expression. (C ) Exami-
nation of the expression of proproliferative cell
cycle genes 48 h after induction of OIS by RT-
qPCR demonstrates that MLL1 knockdown (KD)
OIS cells have dramatically decreased levels of
mRNA of these genes after just 48 h, even in com-
parisonwith SCOIS cells. This 48-h period reflects
the early hyperproliferative and hyperreplicative
phaseprior toOISonsetthat is required forDDRac-
tivation.Consistentwith this,CDK2 is actuallyel-
evated at this time in SC OIS cells in comparison
with SC cells but is significantly decreased already
inMLL1knockdownOIScells. (D)Cells arrested in
G1 phase by serumstarvation are unable to up-reg-
ulateSASP-like inflammatorygeneswhenexposed
to DNA-damaging chemotherapy such as etopo-
side, consistent with previous data showing that
S phase is required in order to activate the DDR
(DiMiccoetal. 2006). (E) Schematic representation
of how MLL1 inhibition (right side) blocks SASP
expression by directly inhibiting the expression of
numerous proproliferative cell cycle genes, thus
preventing the required hyperproliferative and
hyperreplicative phase necessary for activation of
the ATM-mediated DDR and its resulting SASP,
in comparisonwithnormalOIS cells (left side).De-
spite this lack of DDR, MLL1-inhibited cells still
undergo normal tumor-suppressive growth arrest.
MLL1 inhibition prevents inflammation
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Materials and methods
Cell culture
IMR90 cells (obtained from Coriell Institute for Medical Re-
search) were grown in DMEM without phenol with 10% FBS
and 1% penicillin/streptomycin at 3% oxygen. The cells were
generated by retrovirally infecting normal IMR90 fibroblasts
with pLNCX-ER:Ras, and senescence was induced with 4-OHT
(Sigma-Aldrich). MCF7 breast cancer cells (obtained fromCoriell
Institute for Medical Research) were grown in DMEM with 10%
FBS and 1% penicillin/streptomycin at 20% oxygen. Primary hu-
man melanocytes were obtained from normal human foreskin.
After an overnight incubation in dispase, the epidermis was sep-
arated from the dermis and treated with trypsin for 10 min. Cells
were pelleted and plated on selective MC Medium 254 (Gibco)
with human melanocyte growth supplement and 1% penicillin/
streptomycin. Doxycycline (hyclate) hydrochloride (Sigma-Al-
drich) was dissolved in sterile, deionized water. Senescent cells
were maintained in dishes for 10 d to ensure growth termination.
Senescencewas determined bymonitoringCDKN2A/P16 up-reg-
ulation and down-regulation of cyclin genes and by SA-β-gal
(Chemicon International). To arrest cells inG1 phase, serum star-
vation experiments were performed by allowing cells to reach
confluency and then removing serum for 4 d prior to harvesting
the cells for RNA.
Viral transfection and transduction
diBRAF melanocytes were generated by inserting the human
BRAFV600E gene immediately after the TetO operator in a mod-
ified version of the doxycycline-inducible lentiviral pTRIPZ vec-
tor (Thermo Scientific) in which the shRNA hairpin sequences
were deleted. HEK293T cells were then seeded at 70% conflu-
ency onto six-well plates and incubated in DMEM with 5% FBS
and 1% antibiotic and anti-mycotic. Lentiviral plasmid (1.22
µg) was mixed with packaging plasmids pCMVΔR8.91 (0.915
µg) and pUC-MDG (0.305 µg). Plasmids were then mixed with
96 µL of DMEM and 7.2 µL of Fugene6 transfection reagent
(Promega) and incubated for 15 min at room temperature. The
plasmid solution was then added to the cell medium. Sodium
butyrate (10 mM) was added after 16 h, and the cell growth medi-
um was replaced after 24 h and incubated at 32°C. Viral superna-
tant was collected 45 h after transfection and filtered using a
0.45-µm syringe filter (Argos). Melanocytes seeded at 2.5 × 105
cells per well were incubated in the viral supernatant in the pres-
ence of 5 µgmL−1 polybrene and centrifuged at 300g for 60min at
room temperature. Cells were then incubated for 15 min at 37°C
followed by removal of the viral supernatant and replacement
with complete growthmedium. For theMLL1 knockdown exper-
iments,MLL1 and SC shRNAswere generously donated from the
Hua laboratory at the University of Pennsylvania (http://www
.afcri.upenn.edu/ourfaculty/hua_lab.html). Two MLL1 shRNAs
were used:MLL1 shRNA 12 (TTAAATTAGGATAATACCGCG)
and MLL1 shRNA 14 (AATTATGGTCAAGTGAAGGCG). For
the viral transfections, melanocytes and IMR90 fibroblasts were
infected with virus at 60% confluency on 10-cm2 plates for 24 h
in the presence of polybrene. Forty-eight hours following infec-
tions, cells underwent selection with puromycin to obtain
completely puromycin-resistant cell populations. ForMLL1 over-
expression studies, we used Flag-tagged MLL1-pCXN2, which
was a kind gift from Paolo Sassone-Corsi and has been described
before (Katada and Sassone-Corsi 2010). Flag-tagged MLL1-
pCXN2 (4 µg) and GFP (2 µg) were transfected into IMR90 fibro-
blasts using Continuum transfection reagent (Gemini Bio-
Products) according to the manufacturer’s protocol at the same
time as MI-2-2 and were harvested for RNA analyses 48 h later.
Migration assay
MCF7 breast cancer cells were grown to confluency. Next, uni-
form cross-shaped “wounds” were created with a pipet tip. Cells
were photographed on day 1 and then incubatedwith conditioned
medium derived from either SC, SC OIS, or MLL1 knockdown
OIS cells. Conditioned medium was taken from day 10 serum-
free medium that was filtered, and cells were counted to ensure
equal dosing of conditioned medium. Cell medium was changed
on day 2 with fresh conditioned medium, and cells were then im-
aged on day 4. For image analysis, images were loaded into a
numpymatrix using numpy-1.10.1. The inverse of the luminance
of the images was calculated using scikit-image-0.11.3. Values
greater than the mean +1 standard deviation for each image
were retained and appeared to give accurate representations of
cell density. The sumof the inverse luminancewas used as amet-
ric of cell count. The difference of this value was calculated be-
tween images.
ELISA array
Conditioned medium from two biological replicates harvested as
described above was incubated overnight on a RayBio C-Series
human inflammation antibody array (RayBiotech) following
the manufacturer’s protocol. Arrays were imaged by a Fujifilm
LAS-4000 imager. Image analysis was performed using Licor Im-
age Studio Lite. Each dot was assigned a value, and the average of
two measurements was calculated for each array. The average
density values for each cytokine in each condition were then av-
eraged for each array in order to calculate the fold change compar-
ing [−(SCOIS/MLL1 knockdownOIS)], which is shown in blue in
Figure 1.
Growth curve measurement
Cells (200,000) were seeded on a 950-mm2 surface area (one well
of a six-well plate) on day 0. Cell number was measured every 2 d
with a Countess automated cell counter (Life Technologies) fol-
lowing standard procedures and default parameter settings, after
which 200,000 cells were plated back for the next count. Inhibitor
or DMSO vehicle control was added on day 0 as cells were seeded
and was refreshed every other day as cells were counted and re-
plated. An average of two biological replicates is presented with
error bars displaying the standard error of the mean.
RNA-seq
RNAwas extracted using RNeasy kit (Qiagen catalog no. 74014)
following themanufacturer’s instructions. The control (CTL) and
OIS libraries were prepared using TruSeq RNA sample prepara-
tion kit (catalog no. FC-122-1001) with 1 µg of RNA per sample.
The libraries were then sequenced on an Illumina Genome Ana-
lyzer IIx platform (36-base-pair [bp] paired-end). Ras control and
OIS IMR90s were collected at population doubling 32. The
RNA-seq libraries for the SC, SC OIS, and MLL1 knockdown
OIS cells were made using a ScriptSeq version 2 RNA-seq library
preparation kit from Epicentre (now Illumina) and sequenced us-
ingNextSeq platform (50-bp single-end reads) (Illumina). Theme-
lanocyte RNA-seq and expression data for uninfected and BRAF-
infected cells were downloaded from Gene Expression Omnibus
(GEO; accession no. GSE46818). All RNA-seq FPKM (fragments
per kilobase per million mapped fragments) generation was per-
formed in the followingmanner: Paired-end data were aligned us-
ing RNA STAR version 2.3.0e under default settings, Homo
sapiens ENSEMBL release 75. Cufflinks version 2.2.1 was used
to map reads of the aligned SAM files quantitatively to exons
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and gene features (-G parameter). All tRNA, rRNA, and mtRNA
transcripts, downloaded from the University of California at San-
ta Cruz (UCSC) goldenPath database, were masked from the
counting procedure. The ENSEMBL Homo sapiens release
GRCh37.75 was used as the feature table. All other Cufflinks set-
tings were the default parameters. All data were tabulated, aver-
aged, and analyzed using the Python pandas library.
RT-qPCR
RNAwas extracted usingRNeasy kit (Qiagen) following theman-
ufacturer’s instructions. cDNA was obtained and then analyzed
by standard qPCR methods on a 7900HT Fast real-time PCR
(ABI). Primer sequences are available on request. RT-qPCR data
analysis was performed by first obtaining the normalized QT val-
ues (normalized to 18S ribosomal RNA). At least three biological
replicates were performed for every experiment. For the MLL1
knockdown experiments, the data were transformed across tech-
nical and biological replicates to their z-scores (mean subtracted,
variance divided) to account for the variation in sample material
and the reported variability. TheMann-WhitneyU-test was used
to test for and calculateP-values for the differences in sample pop-
ulations between experiments of biological replicates. For all
other studies, the average and standard deviations of biological
replicates were obtained and assessed for significance using an
unpaired t-test (http://www.graphpad.com). For all experiments,
three asterisks indicates P < 0.01, two asterisks indicates P < 0
.05, one asterisk indicates P < 0.1, and NS indicates nonsignifi-
cance (P > 0.1).
Western blots
Cells were lysed in buffer containing 50 mM Tris (pH 7.5),
0.5 mM EDTA, 150 mM NaCl, 1% NP40, and 2% SDS supple-
mented with 1:100 Halt protease inhibitor cocktail (Thermo Sci-
entific). The lysates were incubated for 10 min on ice, boiled for
8–10 min at 95°C, and spun down. The supernatant then under-
went electrophoresis on a 3%–8% Tris-acetate gel for larger pro-
teins and on a 12% Bis-Tris gel for smaller proteins (NuPAGE).
After transfer to nitrocellulose membrane, 5% milk in TBS sup-
plemented with 0.1% Tween 20 (TBST) was used to block the
membrane for 1 h at room temperature. Primary antibodies
were diluted in 5% BSA in TBST and incubated overnight at
4°C. Primary antibodies are listed below. The membrane was
washed three times with TBST for 10 min each followed by incu-
bation of HRP-conjugated secondary antibodies for 1 h at room
temperature in 5% BSA/TBST. Themembrane was washed again
three times and imaged by Fujifilm LAS-4000 imager.
IF
Control and OIS cells were fixed in 4% PFA in PBS for 20 min at
room temperature. Cells were washed twice with PBS and per-
meabilized with 0.5% Triton X-100 in PBS for 10 min. After
washing twice, cells were blocked in 10% BSA in PBS for 1 h at
room temperature. Cells were incubated with primary antibodies
in 5% BSA in PBS supplemented with 0.1% Tween20 (PBST)
overnight at 4°C. Antibodies are listed below. Next, cells were
washed four times with PBST for 10 min each followed by incu-
bation with fluorophore-conjugated secondary antibody in 5%
BSA in PBST for 1 h at room temperature. Cells were thenwashed
three times in PBST and once with PBS and incubated with 1 µg/
mL DAPI for 5 min. The cells were then washed twice with PBS
and mounted with ProLong Gold (Invitrogen). For the tumor sec-
tions, following washes in xylene, ethanol, water, and PBS, sec-
tions were treated with target unmasking fluid to deparaffinize
the tissues. Sections were then blocked for 2 h in 3% goat serum
followed by incubation in primary antibody overnight. Following
secondary antibody incubation and washes, the sections were
incubated with 1 µg/mL DAPI for 5 min, washed twice with
PBS, and mounted with ProLong Gold with DAPI (Invitrogen).
The slides were observed and imaged using a Nikon Eclipse
microscope. Microscopy settings were unchanged between
SC, SC OIS, and MLL1 knockdown OIS samples as well as be-
tween SC and MLL1 shRNA-treated xenograft tumors. For the
in vitro cell counts, three independent counts of 100 cells for
each condition were performed, and cells were scored positive if
they contained at least five positively staining fluorescent nucle-
ar puncta. Similarly, for the tumor sections, three independent
20× fields were scored for positively staining cytokine foci. P-val-
ues were obtained based on a t-test for the relative difference of
means (http://www.graphpad.com).
Antibodies
Antibodies included anti-Histone H3 (Abcam, ab1791), anti-His-
tone H3 (trimethyl K4) (Abcam, ab8580), anti-γH2A.X (phospho-
S139) (Abcam, ab2893), anti-IL1α (Abcam, ab9614), anti-IL6
(Developmental Studies Hybridoma Bank, CPTC-IL6-1), anti-
phospho-NF-κB p65 (Ser536) (93H1) (Cell Signaling, 3033), anti-
ATM (Bethyl Laboratories, A300-299), anti-MLL1 (Bethyl Labora-
tories, A300-086A), anti-ATM (phospho-S1981) (Abcam,
ab81292), anti-β-Tubulin (Sigma, T8328), anti-Ras (Millipore,
05-516), anti-p53 (Pantropic) (Calbiochem, OP43), anti-ATR
(Bethyl Laboratories, A300-137A), anti-phospho-p53 (Ser15)
(Cell Signaling, 9284), and anti-CDKN2A/p16INK4a (Abcam,
ab16123).
Tumor xenograft assay
A total of four male and four female mice (Mus musculus strain
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ; Jackson Laboratories, stock
no. 005557) between the ages of 38 and 45 d old were used per
treatment for tumor xenograft experiments. All animal experi-
ments described adhere to policies and practices approved by
the University of Pennsylvania Institutional Biosafety Commit-
tee (IBC) and the Institutional Animal Care and Use Committee
(IACUC). Cells were collected after shRNA-mediated (MLL1 or
SC) knockdowns. Next, 1.5 million cells were injected subcuta-
neously per mouse. All mice were euthanized 20 wk after subcu-
taneous injection. Tumors were then excised and frozen. Thirty
milligrams of tumor tissue was harvested from each animal for
subsequent RNA extraction and RT-qPCR experiments as de-
scribed above. Tumor sections were cut from formalin-fixed par-
affin-embedded tissues and stained for IF as described above.
Tumor growth characteristics were as previously reported (Zhu
et al. 2015).
Inhibitor assays
The following pharmacologic inhibitors were used: KU55933
(ATM kinase inhibitor) at 10 µM (Selleckchem.com), etoposide
at 100 µM (Sigma Aldrich, E1383), and MI-2-2 (MLL1-Menin in-
teraction inhibitor) at 10 and 20 µM (Millipore).
ChIP-seq
Cells in 10-cm2 dishes were fixed in 1% formaldehyde for 5 min,
and fixationwas quenchedwith addition of glycine to 125mM for
an additional 5 min. Cells were harvested by scraping from plates
and were washed twice in 1× PBS before storage at −80°C. ChIP
was performed as previously described (Shah et al. 2013) except
MLL1 inhibition prevents inflammation
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that extracts were sonicated nine times for 5 min each round (30
sec of sonication with intermediate incubation of 30 sec per
round) using a Bioruptor (Diagenode). All ChIPs were performed
using 500 µg of extract and 2 µg of antibody per sample. Thirty
microliters of Protein G Dynabeads (Invitrogen, 100.02D) was
used per ChIP. ChIP DNA was also used to make sequencing li-
braries using NEBNext (New England Biolabs). Libraries were
quantified (Kapa Biosystems), and sequencing was performed on
either Hi-Seq or NextSeq platforms (50-bp, single-end reads) (Illu-
mina). After sequencing, all data were demultiplexed from the
raw reads using Illumina’s BCL2Fastq version 2.15. Demulti-
plexed data or Fastq files directly output from a Hi-Seq were
aligned to UCSC reference genome build hg19 downloaded
from iGenomes. Alignments were generated with Bowtie 2.2.4,
allowing for one distinct alignment and one mismatch per seed
region (-N1 -K1). All other default parameters were used. Reads
were counted to 100-bp fixed bins using featureCounts from the
Subreads package version 1.4.6-p2. Normalized TPTM was
used. Input was subtracted from γH2A.X, while all H3K4me3
tracks had H3 divided to account for the extensive histone loss
seen in senescence. Tracks were visualized using the UCSC ge-
nome browser. For Figure 4B, the analysis was done on all genes
that had at least a 1.5-fold or greater increase in expression from
CTL to OIS as well as at least a 1.5-fold decrease from OIS to
MLL1 knockdown OIS cells. Of these genes, the topographic lev-
els of H3K4me3 over the TSS (±1 kb) and γH2A.X over the gene
body (normalized by gene length) was counted using the Python
package HTSeq version 0.6.1p2. The TSSs of these genes were
sorted by mean H3K4me3 fold change enrichment in OIS over
CTL cells. The topographic distribution of reads was visualized
using Python package Seaborn version 0.5.1. The heat maps
show log2 fold change of (in order from left to right) H3K4me3
in OIS over CTL cells, H3K4me3 in MLL1 knockdown OIS over
OIS cells, γH2A.X in OIS over CTL cells, and γH2A.X in MLL1
knockdown OIS over OIS cells. The final heat map is the visual-
ization of the RNA-seq log2 fold change in OIS over CTL and
MLL1 knockdown OIS over OIS. For Supplemental Figure S3A,
aligned ChIP-seq reads were mapped to features using the
ENSEMBL GRCh37.75 gene table (GTF from iGenomes). The
top 1%of themost highly up-regulated genes inOISwas then cal-
culated, identified by taking the log of the fold change of OIS ex-
pression over control expression. The log of the fold change inOIS
over control of the γH2A.X andH3K4me3 read density over these
genes was then calculated. The joint relationship between the ex-
pression and the γH2AX fold change was plotted. The genes were
then colored by their relative fold change in H3K4me3.
TCGA analysis
RNA-seq data sets from breast invasive carcinoma and prostate
adenocarcinoma were obtained from TCGA (https://tcga-data
.nci.nih.gov/tcga). Original RNA expression values (normalized
read counts) were used for downstream analyses. For each cancer
type, samples were ranked by MLL1 expression levels and were
evenly divided into three groups. Comparisons were performed
between the group of samples with the highest MLL1 expression
and the group of samples with lowest MLL1 expression. One-sid-
ed Wilcoxon rank sum tests were used to compute significance.
For the ATM analyses, TCGA data were derived from cBioPortal
for Cancer Genomics (http://www.cbioportal.org) (Cerami et al.
2012; Gao et al. 2013), and scatter plots were generated by query-
ing all cancers that have RNA-seq expression data and generating
lists of genes coexpressed with ATM. We ranked the cancers by
their specific Pearson correlation between ATM and MLL1 and
then ranked the mean Pearson correlation among all of the can-
cers for each gene and placed the genes in rank order.
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